SCHEMBL14545235

SCHEMBL14545235

Bc1cnn2c(NCCCNS(=O)(=O)c3cc(F)cc(F)c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 7/20 0.43
▸ GSK3B P49841 7/20 0.43
▸ CCNA2 P20248 1/20 0.34
▸ CCNA1 P78396 1/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ CYP2D6 P10635 2/20 0.34
▸ CYP2C19 P33261 2/20 0.34
▸ BRAF P15056 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13288967 0.98 CDK2 (0.43) CDK2GSK3BCCNA2CCNA1CYP1A2
SCHEMBL13289297 0.95 CDK2 (0.44) CDK2GSK3BCCNA2CCNA1CYP1A2
SCHEMBL13289033 0.92 GSK3B (0.45) CDK2GSK3BCCNA2CCNA1CYP1A2
SCHEMBL12954453 0.91 CDK2 (0.44) CDK2GSK3BCYP1A2CYP2D6CYP2C19
SCHEMBL13289499 0.90 GSK3B (0.44) CDK2GSK3BCCNA2CCNA1CYP1A2
SCHEMBL12954136 0.90 GSK3B (0.44) CDK2GSK3BCCNA2CCNA1CYP1A2
SCHEMBL13121069 0.90 CDK2 (0.56) CDK2GSK3BCCNA2CCNA1
SCHEMBL13288972 0.90 CDK2 (0.44) CDK2GSK3BCYP1A2CYP2D6CYP2C19
SCHEMBL13289474 0.90 GSK3B (0.46) CDK2GSK3BCYP1A2CYP2D6CYP2C19
SCHEMBL13289270 0.90 CDK2 (0.46) CDK2GSK3BCYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007044449-A2 NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2007-04-19 — — WO disclosed
Send feedback